Summary:

Patients with active myeloma, especially with earlier stages of the disease, are susceptible to COVID-19 infection and can have adverse outcomes, even in those on first-line treatment. Importantly, myeloma therapy can be safely administered, and optimal control of myeloma is associated with improved outcome.

See related video:https://vimeo.com/486246183/559a80cfae

See related article by Hultcrantz et al., p. 234.

You do not currently have access to this content.